

03-03-91 09420692

Reference cited against  
EP 02 014 370.7

METHYLGENE, INC.

Your Ref: MET-015EPDV2 (1002/016)

Our Ref: 115-76 T2 (New!)

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :	A1	(11) International Publication Number: <b>WO 99/15648</b> (43) International Publication Date: 1 April 1999 (01.04.99)
(21) International Application Number:	PCT/GB98/02820	(74) Agent: TAIT, Brian, Steele; Zeneca Pharmaceuticals, Intellectual Property Dept., Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).
(22) International Filing Date:	17 September 1998 (17.09.98)	
(30) Priority Data:		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(71) Applicants (for all designated States except US):	ZENECA LIMITED [GB/GB]; 15 Stanhope Gate, London W1Y 6LN (GB). ISIS PHARMACEUTICALS [US/US]; 2292 Faraday Avenue, Carlsbad, CA 92008 (US).	
(72) Inventors; and		
(75) Inventors/Applicants (for US only):	KOROPATNICK, Donald, James [CA/CA]; London Regional Cancer Centre, 790 Commissioners Road East, London, Ontario N6A 4L6 (CA). VINCENT, Mark, David [CA/CA]; London Regional Cancer Centre, 790 Commissioners Road East, London, Ontario N6A 4L6 (CA). DEAN, Nicholas, Mark [GB/US]; Isis Pharmaceuticals, 2292 Faraday Avenue, Carlsbad, CA 92008 (US).	

## (54) Title: ANTISENSE OLIGONUCLEOTIDES AGAINST THYMIDYLATE SYNTHASE

## (57) Abstract

Antisense oligonucleotides targeted to sequences in thymidylate synthase (TS) mRNA. In particular the invention relates to antisense oligonucleotides targeted to sequences in the 3' end of TS mRNA, which are both cytostatic on their own when administered to human tumour cell lines, and which also enhance the toxicity of anticancer drugs such as Tomudex. The invention also relates to antisense oligonucleotides targeted to sequences at or near the translation start site at the 5' end of TS mRNA which induce TS gene transcription and enhance cell growth. The invention further relates to a combination product comprising an antisense oligonucleotide in combination with an anticancer agent such as Tomudex (N-(5[N-3, 4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl]-N-methylamino]-2-thenoyl)-L-glutamic acid) or the Zeneca development compound ZD 9331 ((S)-2-(2-fluoro-4-[N-(4-hydroxy-2,7-dimethylquinazolin-6-ylmethyl)-N-(prop-2-ynyl)amino] benzamido)-4-(1H-1, 2, 3, 4-tetrazol-5-yl) butyric acid), and to the use of such a combination product in the treatment of cancer.

## Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

*FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		

## ANTISENSE OLIGONUCLEOTIDES AGAINST THYMIDYLATE SYNTHASE

This invention relates to antisense oligodeoxynucleotides targeted to sequences in thymidylate synthase (TS) mRNA. In particular the invention relates to antisense oligodexynucleotides targeted to sequences in the 3' end of TS mRNA, which antisense oligodeoxynucleotides are both cytostatic on their own when administered to human tumour cell lines, and also enhance the toxicity of the anticancer drugs such as Tomudex administered to those cells. In contrast, antisense oligodeoxynucleotides targeted to sequences at or near the translation start site at the 5' end of TS mRNA have either no effect, or enhance cell growth, when administered on their own. In addition, antisense nucleic acids targeted to these 5' sequences (but not to 3' sequences) induce TS gene transcription. The invention also relates to a combination product comprising an antisense oligodeoxynucleotide in combination with an anticancer agent such as Tomudex (N-(5-[N-(3,4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N-methylamino]-2-thenoyl)-L-glutamic acid) or the Zeneca development compound ZD 9331 ((S)-2-(2-fluoro-4-[N-(4-hydroxy-2,7-dimethylquinazolin-6-ylmethyl)-N-(prop-2-ynyl)amino]benzamido)-4-(1H-1,2,3,4-tetrazol-5-yl)butyric acid), and to the use of such a combination product in the treatment of cancer.

Thymidylate synthase (TS) (EC 2.1.1.45) catalyses the conversion of deoxyuridylate to thymidylate, and is a housekeeping enzyme essential for the only intracellular *de novo* synthesis of thymidylate (Danenberg, 1977). TS gene expression is tightly regulated with respect to cell proliferation state (Maley and Maley, 1960; Lochsin *et al.*, 1979). As such, the TS gene is part of a group of genes whose expression is elevated at the G<sub>1</sub>/S cell cycle boundary, and it has been suggested that transcription of several S-phase genes (including dihydrofolate reductase and thymidine kinase) is controlled in part by the E2F family of transcription factors (Farnham *et al.*, 1993; Mudrak *et al.*, 1994). In fact, transfection of active E2F1 genes into mouse cells induces expression of TS and other S-phase and cell cycle-regulated genes (De Gregori *et al.*, 1995). As cells progress through the cell cycle from G<sub>0</sub> through S phase, TS mRNA levels increase approximately 20-fold and TS enzyme activity increases about 10-fold (Navalgund *et al.*, 1980). However, TS gene transcription rate is upregulated only 2 to 4 times, suggesting that post-transcriptional events play a major role in TS regulation (Ayusawa *et al.*, 1986; Jenh *et al.*, 1985; Johnson, 1994). Differences in TS

-2-

mRNA stability are not likely to be critical in regulation, as TS mRNA half-life is about 8 hours in both resting and growing rodent cells (Jenh *et al.*, 1985). On the other hand, TS mRNA translation appears to be regulated by the TS protein itself, which specifically interacts at two sites within its own mRNA to inhibit protein production (Chu *et al.*, 1991, 1993b, 5 1994; Voeller *et al.*, 1995). Translation of other mRNAs (including c-myc mRNA) may also be regulated by interactions with TS protein (Chu *et al.*, 1995).

Because of its role in DNA precursor synthesis, TS has been identified as a potential target for cancer chemotherapeutic agents (Hardy *et al.*, 1987). High TS levels have been correlated with poor prognosis in patients with ovarian cancer (Suzuki *et al.*, 1994), rectal 10 cancer (Johnston *et al.*, 1994) childhood acute non-lymphoblastic leukaemia (Volm *et al.*, 1994), and non-small cell lung carcinoma (Volm and Mattern, 1992). However, its prognostic value is not high in all tumour types (Peters *et al.*, 1986, 1994). Two types of TS inhibitors 15 have been developed: (a) nucleotide analogues (including 5-FU, its riboside, and deoxyriboside derivatives) which must be activated to 5-fluorodeoxyuridylate (FdUMP) within cells to be effective (Heidelberger *et al.*, 1983) and (b) 5,10-CH<sub>2</sub>FH<sub>4</sub> (antifolate) analogues, including N-10-propargyl-5,8-dideazafolate (CB3717) (Calvert *et al.*, 1986) and Tomudex (ZD1694; N-[5-(N-[3,4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl]-N-methylamino)-2-thenoyl]-L-glutamic acid) (Jackman *et al.*, 1991a, 1991b). Although 20 Tomudex and 5-FU inhibit TS and have potent cytotoxic and antitumour activity (Heidelberger *et al.*, 1983; Keyomarsi *et al.*, 1993), they have an unusual biochemical effect. When human cancer cell lines are treated with 5-FU or Tomudex, TS levels increase rapidly, perhaps as a result of the release of translational inhibition by the TS protein (Keyomarsi *et al.*, 1993; Chu *et al.*, 1990; Chu *et al.*, 1993a).

It has been speculated that the release of translational inhibition that accompanies 25 binding and inactivation of TS by chemotherapeutic agents (including Tomudex and 5-FU) might be prevented by treating cells with agents that could replace the specific interaction between TS mRNA and TS protein, and inhibit translation (Keyomarsi *et al.*, 1993) but no such agents were described. In another speculative article it was hypothesised that antisense nucleic acids designed to both reduce the ability of TS mRNA to direct protein production, 30 and to interact with the TS protein binding site, may be useful in complementing the effectiveness of drugs targeted against TS (Rapaport *et al.*, 1992).

In previous patent applications, UK 9720107.3 and UK 9722012.3, we disclosed how to specifically down-regulate the expression of TS in human breast cancer (MCF-7) cells in two ways. First, we both transiently and stably transfected the cells with vectors expressing antisense RNA molecules directed to hybridise to three different regions of the TS mRNA.

5 Targeted sequences were: (1) sequences participating in the formation of a putative stem-loop structure surrounding the translation start site, and immediately adjacent and 3' to that site (these sequences also participate in binding TS protein to modulate translation), (2) the exon1/exon2 boundary and (3) the 3' end of the mature cytoplasmic mRNA. Antisense TS RNA was expressed from these vectors (as assessed by northern blot analysis and a novel

10 modification of the run-on transcription assay to measure antisense transcription against background constitutive TS gene expression) (Koropatnick *et al.*, 1997). Second, we transiently transfected cells with single-stranded oligodeoxynucleotides targeted to hybridise to: (a) the translation start site and sequences surrounding it, (b) a sequence proximal to the translation start site and participating in the putative stem-loop structure, and (c) the

15 translation stop site near the 3' end of the mature cytoplasmic RNA.

The present invention is based on our discovery that an antisense oligonucleotide, oligo 83, complementary to a sequence in the TS mRNA 3' untranslated region, down-regulated the level of TS mRNA and protein, inhibited cell proliferation and enhanced the cytotoxicity of TS-directed chemotherapy drugs.

20 In a first aspect of the invention we provide an antisense oligodeoxynucleotide which hybridises to a target nucleic acid sequence in thymidylate synthase and which selectively inhibits thymidylate synthase production in mammalian cells. Preferably the oligonucleotide is targeted to sequences at or near the translational stop site at the 3' end of the TS gene, which sequences lie in the region between bases 800 and 1600, using the sequence numbering

25 described for human thymidylate synthase mRNA by Takeishi *et al.*, 1985. More preferably the sequences lie in the region between bases 1000 and 1530. Most preferably the sequences lie in the region between bases 1030 and 1460.

30 In a second aspect of the invention we provide an antisense oligodeoxynucleotide which hybridises to a target nucleic acid sequence in thymidylate synthase and which selectively enhances thymidylate synthase production in mammalian cells. Preferably the oligonucleotide is targeted to sequences at or near the translation start site at the 5' end of the

-4-

TS gene, which sequences lie in the region between bases 1 and 300, using the sequence numbering in Takeishi *et al.*, 1985. More preferably the sequences lie in the region between bases 50 and 200. Most preferably the sequences lie in the region between bases 90 and 130.

An antisense oligodeoxynucleotide is an oligonucleotide which is designed to hybridise to a specific region of a target nucleic acid sequence. The target nucleic acid is the TS gene or mRNA transcribed from the TS gene. Preferably the target nucleic acid is the mRNA encoding thymidylate synthase.

The effects of antisense oligonucleotides on thymidylate synthase expression can be measured using procedures which are well known to persons skilled in the art. In the present application, effects on mRNA levels have been measured by Northern blot analysis and nuclear run-on transcription assay, and effects on the growth of human tumour cells have been measured by counting cell numbers using a Coulter counter.

Antisense oligonucleotides to thymidylate synthase may inhibit, stimulate or have no effect on thymidylate synthase expression. Of these, preferred antisense oligonucleotides are those which either inhibit or stimulate thymidylate synthase expression, and particularly preferred antisense oligonucleotides are those which inhibit thymidylate synthase expression.

By inhibition of thymidylate synthase expression we mean inhibition of at least 10% relative to the untreated control, measured at day 4 using the assay described in Example 1.2. Preferably inhibition of thymidylate synthase expression is at least 20% and most preferably inhibition is at least 40%.

By stimulation of thymidylate synthase expression we mean stimulation of at least 10% relative to the untreated control, when measured at day 7 using the assay described in Example 1.2. Preferably stimulation is at least 20% and most preferably stimulation is at least 40%.

Preferably, the antisense oligonucleotides are from about 8 to about 50 nucleotides in length, more preferably from about 12 to about 40 nucleotides in length and most preferably from about 16 to about 30 nucleotides in length.

Specific examples of sequences of antisense oligonucleotides which regulate thymidylate synthase activity are shown in Table 1. The regions of TS mRNA targeted by the oligonucleotides are shown in Figure 7.

***Table 1:***

ANTISENSE OLIGONUCLEOTIDE	SEQUENCE
OLIGO 83	TTAAGGATGTTGCCACTGGC
OLIGO 86	AATGGCTGTTAGGGTGCTT
OLIGO 90	TGTGGCCGGCTCGGAGCTGC
OLIGO 91	GCGCCATGCCTGTGGCCGGC
OLIGO 92	GCGCCATGCCTGTGGCCGGC
OLIGO 93	CCCGCCCGCCGCGCCATGCC
ODN 32	ATGCGCCAACGGTTCTAAA
PAS/TSS	UGUGGCCGGCUCGGAGCUGCCGCGCCGGCC
PAS/EXON1,2	GCUACAGCCUGAGAGAUGAAUUCCCUCUGC

It will be appreciated that the invention is not restricted merely to those specific antisense oligonucleotides which are disclosed in Table 1 above but encompasses 5 oligonucleotides of from about 8 to about 50 nucleotides in length which selectively inhibit or selectively enhance thymidylate synthase production and which are selected from those regions of the TS gene which are described hereinbefore.

Hybridisation of an antisense oligonucleotide to its target nucleic acid sequence is mediated by the formation of hydrogen bonds between complementary bases on each nucleic 10 acid strand. Hybridisation may occur between nucleic acid strands which have varying degrees of complementarity, depending on the hybridisation conditions employed. The term "specifically hybridisable" is used to describe an oligonucleotide which has a sufficient degree of complementarity to ensure stable, specific binding to its target sequence, whilst avoiding non-specific binding to non-target sequences.

15 Antisense oligonucleotides may be designed to hybridise to any region within the thymidylate synthase mRNA molecule, including the coding region, the 5' untranslated region, the 3' untranslated region, the 5' cap region, introns and intron/exon splice junctions.

Hybridisation of the antisense oligonucleotide to thymidylate synthase mRNA may affect any aspect of mRNA function, for example mRNA translocation, mRNA splicing, 20 mRNA translation, or the feedback inhibition mechanism regulated by the binding of

thymidylate synthase protein to binding sites within the thymidylate synthase mRNA molecule.

An oligonucleotide is a polymeric molecule which is assembled from nucleotide or nucleoside monomers. The monomers may consist of naturally occurring bases, sugars and inter-sugar linkages or may also contain non-naturally occurring derivatives which modify the properties of the oligonucleotide, for example, phosphorothiorated oligonucleotides have been used in the present application to increase resistance to nuclease degradation.

Preferred oligonucleotides may contain phosphorothiorates, phosphotriesters, methyl phosphonates or short chain alkyl, cycloalkyl or heteroatomic intersugar linkages. Other preferred oligonucleotides may be methoxy-ethoxy winged or may contain a peptide nucleic acid backbone. Particularly preferred oligonucleotides are those containing phosphorothiorates (Summerton, J.E. and Weller, D.D., U.S. Patent No: 5,034,506).

The oligonucleotides may be manufactured using any convenient method of synthesis. Examples of such methods may be found in standard textbooks, for example "Protocols for Oligonucleotides and Analogues; Synthesis and Properties," Methods in Molecular Biology Series; Volume 20; Ed. Sudhir Agrawal, Humana ISBN: 0-89603-247-7; 1993; 1<sup>st</sup> Edition.

In a further aspect of the invention, there is provided a pharmaceutical composition comprising an antisense oligonucleotide targeted to thymidylate synthase as defined hereinbefore in a pharmaceutically acceptable diluent or carrier.

In a further aspect of the invention there is provided a method for the treatment of cancer (or a method for providing an antiproliferative effect) which comprises administering to a warm-blooded animal an effective amount of an oligonucleotide targeted to thymidylate synthase as defined hereinbefore. The invention also provides the use of such an oligonucleotide in the production of a new medicament for the treatment of cancer ( or for the treatment of proliferative disease.

In a further aspect of the present invention, there is provided a combination product comprising an antisense oligonucleotide targeted to thymidylate synthase in combination with an anticancer agent. The antisense oligonucleotide and the anticancer agent may be administered separately, sequentially, simultaneously or in a mixture.

(i) thymidylate synthase inhibitors such as Tomudex (N-(5-[N-(3,4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N-methylamino]-2-thenoyl)-L-glutamic acid) (European Patent Application no. 0239362, Example 7, compound no. 8 therein); Zeneca development compound ZD9331 ((S)-2-(2-fluoro-4-[N-(4-hydroxy-2,7-dimethylquinazolin-6-ylmethyl)-N-(prop-2-ynyl)amino]benzamido)-4-(1H-1,2,3,4-tetrazol-5-yl)butyric acid) (European Patent Application no. 0562734, Example 3 thereof); LY 231514 (Eli Lilly Research Labs, Indianapolis, IN); 1843U89 (Glaxo-Wellcome, Research Triangle Park, NC); AG337 and AG331 (both by Agouron, La Jolla, CA) (Touroutoglou and Pazdur, Clin. Cancer Res., 2, 227-243, 1996).

10

(ii) cytostatic agents such as antioestrogens (for example tamoxifen, toremifene, raloxifene, droloxifene, iodoxifene), progestogens (for example megestrol acetate), aromatase inhibitors (for example anastrozole, letrozole, vorazole, exemestane), antiprogesterogens, antiandrogens (for example flutamide, nilutamide, bicalutamide, cyproterone acetate), LHRH agonists and antagonists (for example goserelin acetate, luprolide), inhibitors of testosterone 5 $\alpha$ -dihydroreductase (for example finasteride), anti-invasion agents (for example metalloproteinase inhibitors like marimastat and inhibitors of urokinase plasminogen activator receptor function) and inhibitors of growth factor function, (such growth factors include for example EGF, FGFs, platelet derived growth factor and hepatocyte growth factor such 15 inhibitors include growth factor antibodies, growth factor receptor antibodies, tyrosine kinase 20 inhibitors and serine/threonine kinase inhibitors).

(iii) antiproliferative/antineoplastic drugs and combinations thereof, as used in medical oncology, such as antimetabolites (for example antifolates like methotrexate, fluoropyrimidines 25 like 5-fluorouracil, FUdR, ftorafur, FdUR, purine and adenosine analogues, cytosine arabinoside); antitumour antibiotics (for example anthracyclines like doxorubicin, daunomycin, epirubicin and idarubicin;) mitomycin-C, dactinomycin, mithramycin; platinum derivatives (for example cisplatin, carboplatin, oxaliplatin); alkylating agents (for example nitrogen mustard, melphalan, chlorambucil, busulphan, cyclophosphamide, ifosfamide, nitrosoureas, thiotepa); 30 antimitotic agents (for example vinca alkaloids like vincristine and taxoids like taxol,

taxotere); topoisomerase inhibitors (for example epipodophyllotoxins like etoposide and teniposide, amsacrine, topotecan).

The anticancer treatment may also be radiotherapy.

5

Particularly preferred anticancer agents are thymidylate synthase inhibitors such as Tomudex (N-(5-[N-(3,4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N-methylamino]-2-thenoyl)-L-glutamic acid) (European Patent Application no. 0239362, Example 7, compound no. 8 therein) and the Zeneca development compound ZD9331 ((S)-2-(2-fluoro-4-[N-(4-hydroxy-2,7-dimethylquinazolin-6-ylmethyl)-N-(prop-2-ynyl)amino]benzamido)-4-(1H-1,2,3,4-tetrazol-5-yl)butyric acid) (European Patent Application no. 0562734, Example 3 thereof).

10 In a further aspect of the present invention there is provided a pharmaceutical composition comprising a combination product as defined hereinbefore and a 15 pharmaceutically acceptable diluent or carrier.

Any pharmaceutical composition as defined hereinbefore may be in a form suitable for oral use, for example a tablet, capsule, aqueous or oily solution, suspension or emulsion; for topical use, for example a cream, ointment, gel or aqueous or oily solution or suspension; for nasal use, for example a snuff, nasal spray or nasal drops; for vaginal or rectal use, for 20 example a suppository; for administration by inhalation, for example as a finely divided powder such as a dry powder, a microcrystalline form or a liquid aerosol; for sub-lingual or buccal use, for example a tablet or capsule; or particularly for parenteral use (including intravenous, subcutaneous, intramuscular, intravascular or infusion), for example a sterile aqueous or oily solution or suspension. In general the above compositions may be prepared in 25 a conventional manner using conventional excipients.

Tomudex is conveniently administered to humans by intravenous injection of a sterile aqueous solution at a dose in the range, for example, of 1 to 4 mg/m<sup>2</sup> of body surface area once every three weeks, preferably at a dose of 3 mg/m<sup>2</sup> once every three weeks.

ZD 9331 is conveniently dosed to humans by oral administration of a solid dosage 30 form or by intravenous injection of a sterile aqueous solution. The oral dosage form is conveniently administered to humans at a total dose in the range, for example, of about 1 to

-9-

100 mg/kg (i.e. about 35 mg/m<sup>2</sup> to 3.5 g/m<sup>2</sup>) every three weeks given by a continuous or an intermittent dosing schedule, for example a dosing schedule of a three week dosing cycle comprising daily doses on days 1 to 5 only followed by no further doses until the next dosing cycle or a dosing schedule of a four week dosing cycle comprising daily doses on days 1 to 14  
5 only followed by no further doses until the next dosing cycle. Preferably the oral dosage form is administered to humans at a total dose in the range, for example, of about 1 to 30 mg/kg every three or four week dosing cycle. The sterile aqueous solution is conveniently administered intravenously to humans at a total dose of up to 100 mg/m<sup>2</sup> every three weeks given by a continuous or an intermittent dosing schedule, for example, a dosing schedule of  
10 one dose per three week dosing cycle, a dosing schedule of a three week dosing cycle comprising daily doses on days 1 to 5 only followed by no further doses until the next dosing cycle, a dosing schedule of a three week dosing cycle comprising doses on days 1 and 8 only followed by no further doses until the next dosing cycle or a dosing schedule of a three week dosing cycle comprising continuous infusion on days 1 to 5 followed by no further dosing  
15 until the next dosing cycle. Preferably the sterile aqueous solution is administered intravenously to humans at a total dose in the range, for example, of about 20 to 50 mg/m<sup>2</sup> every three weeks given by a continuous or an intermittent dosing schedule as illustrated hereinbefore.

The antisense oligonucleotide is conveniently administered to humans by intravenous injection of a sterile aqueous solution at a dose per dosing cycle in the range, for example, of  
20 0.1μg to 1g, preferably at a dose of 1mg to 100mg.

The amount of active ingredient that is combined with one or more excipients to produce appropriate dosage forms will necessarily vary depending upon the particular component of the combination product, the host treated and the particular route of  
25 administration. For example, a formulation intended for oral administration to humans will generally contain, for example, from 0.5μg to 2g of active agent compounded with appropriate and convenient amounts of excipients which may vary from about 5 to about 98 percent by weight of the total composition. A formulation intended for parenteral administration to humans will generally contain 0.1μg to 50mg. Dosage unit forms will  
30 generally contain about 1μg to about 500mg of an active ingredient.

-10-

In a further aspect of the invention there is provided a method for the treatment of cancer (or a method for providing an antiproliferative effect) which comprises administering to a warm-blooded animal an effective amount of a combination product as defined above. The invention also provides the use of such a combination product in the production of a new medicament for the treatment of cancer (or for the treatment of proliferative disease).

Abbreviations used in this application are set out below.

	TS	thymidylate synthase
10	CMV	cytomegalovirus
	5-FU	5-fluorouracil
	LFA	lipofectamine
	PBS	phosphate-buffered saline
	GAPDH	glyceraldehyde-3-phosphate-dehydrogenase
15	FBS	fetal bovine serum
	MT	metallothionein
	ODN	oligodeoxynucleotide
	bp	base pairs
	DMEM	Dulbecco's modified Eagle medium
20	oligo	oligonucleotide

The invention will now be illustrated but not limited by reference to the following Example and Figures wherein:

25        Figure 1 shows that MCF-7 cell growth is inhibited by transfection with antisense TS oligo 86 (targeted to the translation stop site), but is enhanced by transfection with antisense TS oligos 90 or 92 (targeted to sequences at or near the translation start site).

Cells were transiently-transfected with 0.5 or 1.0 µM antisense TS oligonucleotides in Lipofectin as described. Cell numbers were measured by Coulter counter in triplicate flasks 30 after 4 days of growth. Control cells were treated with Lipofectin without oligonucleotides. Cell growth is expressed as a percentage of growth of control cells.

\*: Significantly higher than control ( $p<0.05$ , one way analysis of variants).

\*\*: Significantly lower than control ( $p<0.05$ , one way analysis of variants).

5 *Figure 2* shows that HeLa cell growth is inhibited by transfection with antisense TS  
oligo 86 (targeted to the translation stop site), but is enhanced after transfection with antisense  
TS oligo 91 (targeted to the translation start site).

HeLa cells were transfected with 0.05 or 0.10  $\mu$ M antisense TS oligonucleotides in  
Lipofectin (10  $\mu$ g/ml) for 4 hours as described. Note that oligo concentrations are  
considerably lower than those used for MCF-7 cells. The efficiency of Lipofectin-mediated  
10 DNA transfection of HeLa cells is greater than for MCF-7 cells. Lipofectin was removed, the  
cells were trypsinised, and 25,000 viable cells per flask were plated in tissue culture flasks.  
Cell numbers were measured by Coulter counter in triplicate flasks after 4, 7 and 8 days of  
growth. Control cells were treated with Lipofectin without oligonucleotides. Cell growth is  
expressed as a percentage of growth of control cells.

15 \*: Significantly higher than control ( $p<0.05$ , Student's t-test).

\*\*: Significantly lower than control (Student's t-test).

20 *Figure 3* shows that HeLa cell growth is inhibited by transfection with antisense TS  
oligo 83 (targeted to a 3' untranslated sequence downstream of the translation stop site), but is  
not affected by transfection with antisense TS oligo 81 (targeted to the translation start site).  
The experimental protocol was as described in the legend to Figure 2.

25 *Figure 4* shows that transient transfection of HeLa cells with oligo 86 (targeted to the  
TS translation stop site) enhances sensitivity to Tomudex and that oligo 91 (targeted to the TS  
translation start site) reduces sensitivity to Tomudex.

HeLa cells were transfected with 0.05 and 0.10  $\mu$ M antisense TS oligonucleotides and  
plated in flasks at low density, as described for Figure 2. Tomudex (0-8 nM) was added  
(triplicate flasks for each Tomudex concentration) and the cells allowed to proliferate for 7  
days. Cell numbers were measured by Coulter counting at that time. Survival is plotted as a  
30 percentage of growth in cells transfected with oligonucleotide, but untreated with Tomudex.  
Therefore, these data reveal inhibition or enhancement of Tomudex killing independent of

-12-

growth inhibition or enhancement induced by oligonucleotides in the absence of Tomudex. The mean of three values is plotted. Error bars were smaller than the size of the symbol in each case.

\*: Significantly different from control ( $p<0.05$ , Student's t-test).

5

*Figure 5* shows that transient transfection of HeLa cells with oligo 83 (targeted to a sequence in the 3' untranslated region of TS mRNA) enhances sensitivity to Tomudex whereas oligo 81 (targeted to a 3' sequence downstream of that targeted by oligo 83) has no effect on Tomudex sensitivity.

10 HeLa cells were transfected with 0.10  $\mu$ M antisense TS oligonucleotides and plated in flasks at low density, as described for Figure 2. Tomudex (0-10 nM) was added (triplicate flasks for each Tomudex concentration) and the cells allowed to proliferate for 4 days. Cell numbers were measured by Coulter counting at that time. Survival is plotted as a percentage of growth in cells transfected with oligonucleotide, but untreated with Tomudex. Therefore, 15 these data reveal enhancement of Tomudex killing independent of growth inhibition induced by oligonucleotides in the absence of Tomudex. The mean of three values is plotted. Error bars were smaller than the size of the symbol in each case.

\*: Significantly different from control ( $p<0.05$ , Student's t-test).

20 *Figure 6* shows that antisense TS oligo 91, but not oligo 86, stimulates TS gene transcription in human HeLa cells.

The same HeLa cells for which data are presented in Figure 2 were assessed for run-on transcription of TS, glyceraldehyde phosphate dehydrogenase (GAPDH), and 18S rRNA genes. Briefly, cells were transfected with 0.05 and 0.10  $\mu$ M antisense TS oligonucleotides in 25 Lipofectin (10  $\mu$ g/ml), or with Lipofectin alone (LFA control) for 4 hours as described. Lipofectin was removed and cells were trypsinised and replated in tissue culture flasks. Four days after transfection, nuclei were isolated from approximately  $5 \times 10^6$  cells for each treatment and initiated TS, GAPDH, and 18S rRNA transcripts allowed to incorporate [ $^{32}$ P]-CTP for 30 minutes. Alcohol-precipitable radiolabeled RNA was hybridised for 48 hours to unlabeled 30 TS, GAPDH, and 18S rRNA cDNA immobilised in triplicate dots on nylon membrane as described. Relative transcription rate is presented as:

(hybridisation signal from gene of interest)

Relative transcription rate =  $\frac{\text{(hybridisation signal for gene of interest)}}{\text{(hybridisation signal for GAPDH or 18S rRNA genes)}}$

5

*Figure 7* shows the sequence of human mRNA for thymidylate synthase (EC 2.1.1.45), bases 1 to 1536.

10 *Figure 8:* shows that antisense TS ODN 83 inhibits HeLa cell proliferation. HeLa cells transfected with 50 nM antisense TS ODN 83 (●) or 50 nM scrambled control ODN 32 (○) were assessed for cell proliferation at 1, 2, 5, and 6 days following transfection. Data points indicate the average of two measurements, and are representative of qualitatively similar results obtained in 16 independent experiments.

15 *Figure 9* shows that antisense TS ODN 83 suppresses HeLa cell growth after transfection, followed by recovery to control proliferation rate after 48 hours. HeLa cells were transfected with 50 nM antisense TS ODN 83 or 50 nM scrambled control ODN 32 as described in the legend to Figure 1. Values derived from cells transfected with ODN 32 were normalised to 100%, and each bar indicates the percent of that value measured following 20 treatment with ODN 83 (mean +/- SE of 4 independent experiments). Asterisks (\*) indicate significant differences ( $p<0.02$ , Student *t*-test).

*Figures 10 & 11* show that treatment of HeLa cells with ODN 83 leads to decreased TS mRNA levels.

25 *(Figure 10)* HeLa cells were transfected with ODN 83 or scrambled control ODN 32, or treated with Lipofectamine alone. Cells were harvested at 1, 2, and 4 days post-transfection and total cellular RNA isolated, reverse-transcribed, and TS and GAPDH cDNA amplified by 24 PCR cycles in the same reaction vessel. TS (208 bp) and GAPDH (752 bp) RT/PCR products were confirmed by Southern blotting and hybridisation to specific radioactively-labeled probes.

*(Figure 11)* TS:GAPDH ratio of RT/PCR products from RNA isolated from HeLa cells 1 day

-14-

after transfection with ODN 83 or ODN 32. Twenty-four, 25, 26, or 27 cycles of PCR amplification were carried out, revealing the same reduction in TS:GAPDH ratio after transfection with ODN 83.

5        *Figure 12* shows that TS protein levels (inferred by measurements of 5-FdUMP binding) are diminished by antisense TS ODN 83 but not scrambled control ODN 32. 5-FdUMP binding was measured in cells transfected with ODN 83 (hatched bars) or ODN 32 (open bars) at different times following transfection.

10      (A): Results are plotted as a percent of 5-FdUMP binding in cells transfected with control ODN 32+- SE ( $n=5$ ). The values for ODN 32 ( $n=5$ ) were normalised to 100% and are shown without error bars.

15      (B): Results are presented as pmol 5-FdUMP bound per mg total protein ( $\times 10^{-3}$ ) to reveal that transfection with control ODN 32 had no significant effect on TS protein levels. Error bars indicate errors calculated according to a Student *t*-test, and indicate error due to differences in experimental conditions in 5 measurements taken on different days, and differences due to transfection with different ODNs. The asterisks indicate significant differences ( $p<0.02$ ) determined by using a paired Student *t*-test.

20      *Figure 13*: shows that antisense TS ODN 83 sensitises HeLa cells to the toxic effects of 5-FU, 5-FUDR, Tomudex, and MTX, but not cisplatin or chlorambucil. HeLa cells were transfected with ODN 83 (●) or control ODN 32 (○) and treated with different concentrations of 5-FU (A), 5-FUDR (B), Tomudex (C), MTX (D), cisplatin (E) or chlorambucil (F) for 4 days, beginning 24 h after transfection. Data points are plotted as the mean +- SE of 4 measurements. Where error bars are not apparent, they are obscured by the symbol. Asterisks (\*) indicate significant differences  $<0.02$ , Student *t*-test).

**Example 1****Example 1.1: Experimental Methods**

5

Cell culture:

MCF-7 (human breast adenocarcinoma) cells were cultured in DMEM supplemented with 10% fetal bovine serum (FBS), 2 mM glutamine, 10 mM Hepes (pH 7.4) and 0.1% Gentamycin.

10

Vector construction:

Expression vectors pAS/TSS and pAS/exon1,2 were designed to produce, upon transfection into MCF-7 cells, single-stranded antisense RNA molecules containing double-stranded 30 bp oligonucleotides complementary to the TS mRNA at one of two sites.

15 Oligodeoxynucleotides corresponding to each strand of the human TS cDNA at positions 111 to 140 (pAS/TSS; targeting a 30 bp region adjacent to, and 2 bp away from, the translation start site) or 296 to 325 (pAS/exon1,2; targeting a 30 bp region spanning the exon 1/exon 2 boundary) were synthesized. Numbering of bases was according to GenBank accession no. X02308 (Takeishi *et al.*, 1985). In order to facilitate cloning, six additional nucleotides were incorporated (5 at the 5' end, 1 at the 3' end) of each oligodeoxynucleotide to produce *Hind* III or *Xba* I sticky ends when complementary strands were annealed. Single-stranded oligonucleotides (4 mg each) were annealed in 3X SET (450 mM NaCl, 60 mM Tris-HCl, 3 mM EDTA, pH 7.8) by treating the mixture for 5 min at 90°C, 5 h at 50°C, then 16 h at 25°C. Double-stranded products were identified by gel electrophoresis, and directionally inserted into the *Hind* III and *Xba* I sites of pRC/CMV (Invitrogen Corp., San Diego, CA). The orientation of cloning was confirmed by direct sequencing.

20

Oligodeoxynucleotides:

30 Fully phosphorothioated 20-mer oligonucleotides (ODNs) were synthesized by Isis Pharmaceuticals (Carlsbad, CA). The 6 terminal nucleotides at the 5' and 3' ends of each ODN were 2'-methoxyethoxy-modified to make them resistant to intracellular nucleases and increase

-16-

their stability within cells (McKay *et al.*, 1996), but the internal 8 nucleotides without methoxyethoxy groups were susceptible to RNase H cleavage. Oligo 86 was complementary to TS mRNA from base positions 1035 to 1054 (GenBank accession no. X02308; Takeishi *et al.*, 1985), which surround the TS mRNA translation stop site (UAG at bases 1045 to 1047). Oligo 5 90 was complementary to base positions 111 to 130, which are 3' and proximal to the translation start site (AUG at bases 106 to 109). Oligo 92 was complementary to base positions 101 to 120, including and surrounding the translation start site.

Transfection:

10 Antisense RNA expression vectors were transfected into MCF-7 cells using Lipofectamine (GIBCO BRL, Burlington, ON, Canada), a polycationic liposome formulation. 1.5 X 10<sup>6</sup> cells were dispensed into 100 X 15 mm tissue culture plates and allowed to adhere overnight. Cells were washed once with 3 ml OptiMEM (GIBCO BRL, Burlington, ON, Canada), followed by exposure to 6 ml of a mixture of double-stranded expression vector DNA 15 (0.83 µg/ml) plus Lipofectamine (1.67 µg/ml) in opti-MEM for 6 h at 37°C in a 5% CO<sub>2</sub> incubator. The DNA/Lipofectamine mixture was removed and replaced with 10 ml DMEM with supplements. Control cells were transfected with pRC/CMV vector without insert. Transiently-transfected cells were used within 1 to 6 days. Stably-transfected cells were allowed to recover in complete non-selective medium without Geneticin for 48 h, then grown in the presence of 20 Geneticin (400 µg per ml, active form [Gibco/BRL]) to allow selection of colonies harboring pRC/CMV control vectors, or pRC/CMV vectors expressing RNA complementary to sequences surrounding the translation start site (pAS/TSS).

25 Single-stranded oligodeoxynucleotides (0.5 µM or 1.0 µM) were transiently transfected into 1.5 X 10<sup>6</sup> MCF-7 cells adhering to 100 X 15 mm tissue culture plates, in a total volume of 5 ml in the presence of Lipofectamine (2 µg/ml) in Opti-MEM. Control cells were treated with Lipofectamine/Opti-MEM without added DNA. Cells were washed after 6 h, medium plus supplements added as described above, and then grown for 48 hours before isolation of nuclei for run-on transcription measurement.

30

Southern blot analysis:

**SUBSTITUTE SHEET (RULE 26)**

Total DNA was isolated from pAS/TSS transfected cells as follows. Cells were incubated in lysis buffer (50 mM Tris-HCl [pH8.0], 100 mM EDTA, 100 mM NaCl, 1% sodium dodecyl sulfate, 0.5 mg/ml proteinase K) for 6 h at 55°C. One-third the volume of 6 M NaCl was added to precipitate non-nucleic acids by centrifugation at 10,000 X g for 15 min. The DNA in the supernatant was precipitated in isopropanol and washed with 70% ethanol. DNA was cleaved with *Hind* III for 16 h and analysed by Southern blotting (Sambrook *et al.*, 1989). Blots were hybridized with an [ $\alpha$ -<sup>32</sup>P]dCTP random primer-labeled pAS/TSS probe (Church and Gilbert, 1984), and were exposed to a phosphor screen and quantitated using a PhosphorImager and the ImageQuant program (Molecular Dynamics, Sunnyvale, CA). The nylon membranes were stripped and rehybridized with an *Alu* probe (300 bp of a human *Alu* restriction fragment inserted into pBR322 [Jelinek *et al.*, 1980]) in order to quantitate the amount of human DNA loaded in each lane (Koropatnick *et al.*, 1988).

Northern blot analysis:

RNA was isolated using RNeasy columns (Qiagen Inc., Chatsworth, CA) from cells transfected with the pAS/TSS expression vector. Ten or 15 ug of RNA per lane were separated on a 1.4% formaldehyde gel (Sambrook *et al.*, 1989) and transferred to a Hybond-N nylon membrane. Membranes were hybridized (Church and Gilbert, 1984) with either a pAS/TSS-generated riboprobe (Promega Corp., Madison, WI) designed to bind to antisense RNA, or a random primer-labeled, 1.9 kb *Xho* I fragment from pcHTS-1 (a eukaryotic expression vector containing the human TS cDNA: a generous gift from Dr. K. Takeishi, University of Shizuoka, Shizuoka, Japan)(Takeishi *et al.*, 1985). Blots were stripped and rehybridized with cDNA probes to detect 18S ribosomal RNA or glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Images were quantitated using a PhosphorImager (Molecular Dynamics, Sunnyvale, CA).

25

Isolation of nuclei:

Relative transcription rates were determined by a nuclear run-on assay (Koropatnick *et al.*, 1997), a modification of the methods of Kikuchi *et al.* (1992) and Almendral *et al.* (1988). Nascent transcripts were extended *in vitro* (Marzluff and Huang, 1984) in parallel reactions using MCF-7 cell nuclei isolated 48 h following transient transfection with control or antisense TS RNA expression vectors, or single-stranded antisense TS oligodeoxynucleotides (or

-18-

Lipofectamine alone), and from cells stably transfected with antisense RNA expression vectors. Adherent cells were rinsed twice with ice-cold PBS, scraped off with a rubber policeman, pelleted in PBS (5 min, 500 X g) and lysed by incubating 5 min at 4° C in 4 ml of lysis buffer (10 mM Tris-Cl, pH 7.4, 10 mM NaCl, 3 mM MgCl<sub>2</sub>, 0.5% NP-40). All subsequent steps were  
5 carried out at 4° C. Complete cell lysis and integrity of released nuclei was checked by light microscopy, and nuclei were pelleted by centrifugation at 500Xg for 5 min. Nuclei were then resuspended in 4 ml of lysis buffer by vortexing, pelleted by centrifugation, resuspended in 200 µl of nuclei storage buffer (40% glycerol, 5 mM MgCl<sub>2</sub>, 50 mM Tris-HCl [pH 8.0], 0.1 mM EDTA) in a 15 ml conical polypropylene centrifuge tube, and immediately frozen in liquid  
10 nitrogen and stored at -120° C until use up to one month later.

Run-on transcription:

RNA elongation reactions were performed for 30 min at 30°C using 2 X 10<sup>7</sup> nuclei/400 µl reaction. Reaction mixtures were composed of 200 µl nuclei storage buffer plus 200 µl of  
15 sterile 2X reaction buffer (10 mM Tris-HCl [pH 8.0], 5 mM MgCl<sub>2</sub>, 0.3 M KCl, 1 mM ATP, 1 mM CTP, 1 mM GTP, 5 mM dithiothreitol, and 2 µl [ $\alpha$ -<sup>32</sup>P]UTP or [ $\alpha$ -<sup>32</sup>P]CTP [ $\approx$  3000 Ci/mmol, 10 mCi/ml]). Nucleotides, radionucleotides, and dithiothreitol were added  
immediately prior to use. Nascent RNA transcripts were allowed to elongate for 30 min at 30°C on a shaking platform, followed by addition of 600 µl of RNase-free DNase I (0.04 units RQ1  
20 DNase I [RNase-free; Promega Corp.], 0.5 M NaCl, 50 mM MgCl<sub>2</sub>, 2 mM CaCl<sub>2</sub>, 10 mM Tris-HCl [pH 7.4]). The <sup>32</sup>P-labeled RNA was isolated using Trizol (Gibco/BRL), and the final  
precipitated RNA was dissolved in Church hybridization buffer (1 mM EDTA, 0.5 M NaHPO<sub>4</sub>  
[pH 7.2], 7% sodium lauryl sulphate [SLS]), to a final concentration of 4 X 10<sup>6</sup> cpm per ml.

25 Hybridization of radiolabeled RNA to immobilized unlabeled probes:

In order to distinguish between TS sense and antisense RNA molecules produced in isolated nuclei from transfected cells, target DNA (immobilized on nitrocellulose filters in triplicate dots, 2 µg per dot) consisted of single-stranded synthetic oligonucleotides rather than TS cDNA. Strand-specific oligonucleotide probes were also used to assess levels of human  
30 metallothionein-2 (MT-2) mRNA and antisense RNA as positive and negative controls, respectively. Single-stranded oligonucleotides were immobilized on nitrocellulose filters by

-19-

dissolving in 6XSSC (16 µg per ml) and applying 125 µl per dot using a BioRad dot-blot apparatus. Unlabeled complementary cDNA probes for GAPDH mRNA (Denhardt *et al.*, 1988) and 18S ribosomal RNA (Behrend *et al.*, 1994) were denatured and immobilized on the same nitrocellulose filters (5 µg per dot, triplicate dots) using a previously-described protocol  
5 (Koropatnick, 1988). Hybridization of radiolabeled RNA to these dots assessed transcription of GAPDH and 18S rRNA genes, and acted as internal standards against which to measure changes in TS gene transcription. For cells transfected with single-stranded oligonucleotides, TS gene transcription was assessed by hybridization of radiolabeled TS RNA transcripts to immobilized target DNA consisting of a 1.9 kb *Xho* I fragment isolated from pCHTS-1.

10

Nitrocellulose filters containing triplicate dots of oligonucleotide and cDNA probes to assess run-on transcription of antisense TS RNA expression vectors, and endogenous TS, MT-2, GAPDH and 18S rRNA genes, were prehybridized in Church buffer for 20 min at 65° C in a Hybaid hybridization chamber. The prehybridization buffer was then removed, 2 mls of  
15 radiolabeled RNA resulting from 30 min of run-on transcription in isolated nuclei (in Church hybridization buffer, 4 X 10<sup>6</sup> cpm per ml) was added, and the filters were hybridized for 48 h at 65° C. The filters were then washed twice at 65° C in posthybridization buffer (40 mM Na<sub>2</sub>HPO<sub>4</sub>, 1% SDS; 20 min per wash). Posthybridization buffer was removed and 8 ml of RNase A (1 µg per ml in 6XSSC) was added and incubated for 30 min at 37° C to reduce signal from  
20 unhybridized radiolabeled RNA. After a final wash in posthybridization buffer (10 min, 37° C) filters were blotted dry and bound radioactivity visualized and quantitated using a phosphorimager and the ImageQuant program (Molecular Dynamics, Sunnyvale, CA). Relative transcription of antisense TS expression vectors, endogenous TS genes, and MT-2 genes was defined as:

25

(hybridisation signal from gene of interest)

Relative transcription rate = \_\_\_\_\_  
(hybridisation signal for GAPDH or 18S rRNA genes)

30

TS oligonucleotide probes:

SUBSTITUTE SHEET (RULE 26)

-20-

Bases in bold-face (below) form part of restriction endonuclease sites, and are not sense or antisense TS sequences. Numbering indicates the distance from the beginning of the transcription start site.

5           *TS cDNA nucleotides 111 to 140*

*sense TS (JK-5):*       **CTAGATGTGGCCGGCTCGGAGCTGCCGCCGGCCA**

*antisense TS (JK-2):*   **AGCTTGGCCGGCGCGGCAGCTCCGAGCCGGCACAT**

10          *TS cDNA nucleotides 296 to 325*

10          *sense TS (JK-3):*       **CTAGAGCTACAGCCTGAGAGATGAATTCCCTCTGCA**

*antisense TS (JK-4):*   **AGCTTGCAGAGGAATTCATCTCTCAGGCTGTAGCT**

MT-2 oligonucleotide probes (Karin and Richards, 1982):

15          Sense and antisense oligonucleotide sequences did not have non-complementary sequences added to the 5' and 3' ends. Numbering indicates the distance from the translation start site.

15          *MT cDNA nucleotides -14 to 6*

*sense MT:*       **CTCTTCAGCACGCCATGGAT**

20          *MT cDNA nucleotides 204 to 223*

*antisense MT:*   **AGGGTCTACCTTCTTGCGC**

**Example 1.2: Antisense oligodeoxynucleotide targeting regions at or near the translation stop site at the 3' end of the TS gene as a method to inhibit growth of human tumour cells**

25

a) A 20-mer antisense oligodeoxynucleotide (oligo 86) targeted to the translation stop site at the 3' end of the thymidylate synthase mRNA is growth inhibitory (cytostatic) in a human breast cancer cell line (MCF-7 cells). Antisense oligonucleotides of the same length (oligos 90 and 92), targeted to regions at or near the translation start site at the 5' end of the

30          TS mRNA, are not cytostatic (**Figure 1**).

-21-

b) A 20-mer antisense oligodeoxynucleotides targeted to the TS mRNA translation start site (oligos 91 and 93) did not inhibit growth of a human cervical carcinoma (HeLa) cell line. In fact, growth was significantly enhanced. Antisense oligodeoxynucleotides targeted to the 3' end of the TS mRNA, including the translation stop site (oligo 86) or a sequence in the 5 3' untranslated region (oligo 83) significantly inhibited HeLa cell growth. An antisense TS oligonucleotide targeted to another sequence in the 3' untranslated region of TS mRNA (oligo 81) had no effect on HeLa cell growth (**Figures 2 and 3**).

Therefore, no antisense TS oligodeoxynucleotides targeted to the translation start site 10 were successful in inhibiting growth of two different human tumour cell lines (human breast carcinoma MCF-7 cells or human cervical carcinoma HeLa cells). **Two separate antisense TS oligodeoxynucleotides targeted to the 3' end of the TS gene were potent inhibitors of human tumour cell growth.**

15 **Example 1.3:**

(a) Antisense oligodeoxynucleotide targeting of the thymidylate synthase translation stop site as a method to enhance human tumour cell sensitivity to the toxic effects of Tomudex (ZD 1694).

20

Antisense TS oligodeoxynucleotides (oligos 86 and 83) targeting sequences in the 3' untranslated region of TS mRNA enhanced human cervical carcinoma cell sensitivity to Tomudex. The enhancement in sensitivity was in addition to the directly cytostatic effects of oligos 86 and 83 (**Figures 4 and 5**).

25

(b) Antisense oligodeoxynucleotide targeting of the thymidylate synthase translation start site as a method to enhance human cell resistance to the toxic effects of Tomudex (ZD 1694).

An antisense TS oligodeoxynucleotide (oligo 91) targeting the translation start site of TS mRNA enhanced human cervical carcinoma cell resistance to the toxic effects of Tomudex (**Figure 4**).

5   **Example 1.4: Induction of transcription of genes targeted with antisense nucleic acids as a screening method to identify appropriate target sequences for antisense nucleic acids.**

Human tumour cells appear to compensate for antisense inactivation of specific mRNA by increasing transcription of genes producing the target sequences, a process that can 10 be termed "compensatory transcription", resulting in resistance to the effectiveness of antisense nucleic acids. It has been observed, that TS gene transcription is induced in human MCF-7 breast carcinoma cells by treatment with antisense TS RNA and oligodeoxynucleotides targeted to regions at or near the TS mRNA translation start site. The same phenomenon has been observed in human HeLa cells transiently-transfected with 15 antisense TS oligo 91 (targeted to the translation start site), but not in response to oligo 86 (targeted to the translation stop site) (**Figure 6**). Increased specific gene transcription in response to transfected antisense nucleic acids would indicate that the target sequence is inappropriate to achieve downregulated gene expression. On the other hand, it may be an appropriate sequence to target to achieve upregulated gene expression (to increase resistance 20 to chemotherapeutic drugs, for example, in normal tissues).

In summary, the present invention has demonstrated that antisense oligonucleotides, targeted against selected regions of thymidylate synthase mRNA, can effectively inhibit growth when administered alone. They can also enhance cell killing by Tomudex. Conversely, 25 antisense oligonucleotides targeted to certain mRNA regions (for example, the translation start site) may either be ineffective, or enhance growth and survival during exposure to Tomudex. Ineffectiveness may be due to oligonucleotide-induced TS gene transcription. It is essential to identify TS mRNA regions that may be effectively targeted with antisense sequences to inhibit tumour cell growth and enhance the toxicity of anticancer drugs. Furthermore, the mechanism 30 by which antisense sequences targeted to 5' TS mRNA regions induce TS gene transcription has

important implications for choosing antisense targets in TS mRNA in particular, and for optimising antisense strategies in general.

### Example 2

5

#### **Example 2.1: Experimental Methods**

##### Oligonucleotides:

Fully phosphorothioated 20-base oligonucleotides were synthesised by ISIS Pharmaceuticals (Carlsbad, California, USA). The 6 nucleotides on either end of the oligomer were methoxyethoxylated in the 2'-position, enhancing hybridisation as well as resistance to exonucleation. The middle 8 nucleotides were not methoxyethoxylated to allow RNase H endonucleation and degradation of mRNA hybridised to the oligomer. ODN 83 is complementary to TS mRNA, starting from a position 136 bases downstream of the translational stop site (5'-GCCAGTGGCAACATCCTTAA-3'). ODN 32 is a randomised sequence of ODN 83 (5'-ATGCGCCAACGGTTCTAAA-3'), with the same base constituents in random order. A search of available mRNA sequences using the NCBI BLAST search tool revealed that ODN 83 had sequences of 10 or more complementary bases to only human TS mRNA, while ODN 32 had sequences of 10 or more complementary bases to no known mRNAs.

##### Radioisotope:

[6-<sup>3</sup>H]5-FUDR (specific activity 18.6 Ci/mmol) was purchased from Moravek Biochemicals (Brea, California, USA). This isotope was 99.98% pure upon initial production, with a degradation rate of 0.5-1% per month at -20°C, and was used within 3 months of manufacture.

##### Other supplies:

Cell culture chemicals and nutrients were obtained from Canadian Life Technologies (GIBCO) (Burlington, Ontario, Canada). All other chemicals were obtained from commercial

-24-

sources. Plasticware was purchased from VWR Canlab (Mississauga, Ontario, Canada) and Fisher Scientific Uniondale, Ontario, Canada).

Cell Culture:

5 Human cervical carcinoma HeLa cells were maintained in D-MEM plus 10% foetal bovine serum and penicillin (50 units/ml)/streptomycin (50 µg/ml). Cultures were incubated in a humidified atmosphere of 5% CO<sub>2</sub> at 37°C. Rapidly proliferating cells were utilised for establishing cultures of experimental cells, which were allowed to plate overnight prior to manipulation.

10 Transfection was performed using lipofectamine (LFA, GIBCO-BRL), a polycationic liposome formulation. Cells to be used for proliferation experiments were plated at a starting cell number of between 0.6 and 1 x 10<sup>5</sup> cells per 25-cm tissue culture flask, and LFA was used at 3 µg/ml. For cells in 75-cm flasks, which were to be harvested and extracted for assay of mRNA or TS content, the starting cell number was approximately 8 - 10 x 10<sup>5</sup>, and the LFA 15 concentration was 4 µg/ml. Prior to transfection, adherent HeLa cells were washed once with PBS and then treated with antisense or scrambled control ODN (50 nM) in the appropriate concentration of LFA in serum-free D-MEM, at 37°C for 6.0 h. The cells were then washed once with PBS and cultured in the presence of D-MEM plus 10% FBS. In cells treated with cytotoxic agents, exposure was initiated 24 hours after the removal of LFA/ODN, by addition 20 of 0.2-volume of growth medium containing the agent at 6 times the final concentration. At the time of addition of drug, and after 4 days of incubation, cell numbers were determined from replicate flasks by enumerating with a particle counter (Coulter Electronics, Hialeah, Florida, USA). The proliferation of drug treated cells (fold-increase in cell number) was calculated as a percentage of that of the control cells. IC<sub>50</sub> and IC<sub>90</sub> values were determined by 25 interpolation of plotted data.

RT-PCR to measure TS mRNA:

RNA was isolated from transfected cells using Trizol (GIBCO-BRL). Complementary DNA was synthesised from 1 µg of total RNA using 200 U of Moloney Murine Leukemia 30 Virus reverse transcriptase (GIBCO BRL) in 50 mM Tris-HCl (pH 8.3), 75 mM KCl, 3 mM MgCl<sub>2</sub>, 1 mM mixed dNTPs, 100 pmol random primers and 10 mM dithiothreitol at 37°C for 1

hr. The enzyme was inactivated at 95°C for 5 min. The resulting cDNAs (in a volume of 2.5 µl) were amplified in a polymerase chain reaction (PCR) using 1.25 U of *Taq* DNA polymerase in 50 µl of 20 mM Tris-HCl pH 8.4), 50 mM KCl, 0.2 mM mixed dNTPs, 2 mM MgCl<sub>2</sub>, and 50 pmol of primers specific for TS and GAPDH cDNAs. TS and GAPDH 5 cDNAs were amplified together in the same reaction tube to allow the level of housekeeping GAPDH cDNA to be used to determine the relative level of TS mRNA. Twenty-four to 27 cycles of PCR amplification (94°C 45 s, 55°C 30 s, 72°C 90 s) produced fragments of 208 bp and 752 bp using primer sets for TS (forward 5'CACACTTGGGAGATGCACA3'; reverse 5'CTTGAAAGCACCCCTAACAOCCAT3') and GAPDH (forward 10 5'TATTGGCGCCTGGTCACCA3'; reverse 5'CCACCTTCTTGATGTCATCA3'), respectively. PCR products were separated on a 1.2% agarose gel, and transferred to Hybond nylon membrane (Amersham, Canada, Ltd., Oakville, Ontario, Canada) by Southern blotting. Blots were hybridised to [ $\alpha$ -<sup>32</sup>P]dCTP random primer-labeled probe (pcHTS-1, a generous gift from Dr. K. Takeishi, University of Shizuoka, Shizuoka, Japan; or a cDNA insert recognising 15 glyceraldehyde-3-phosphate dehydrogenase [GAPDH]). Hybridisation signals were quantified using a PhosphorImager and ImageQuant (Molecular Dynamics, Sunnyvale, California, USA).

TS binding assay:

20 Cellular content of TS was assayed by binding of [6-<sup>3</sup>H]5-FdUMP. This method was demonstrated to label total TS unless the cells were pretreated with 5-FU or 5-FUDR. The assay was performed using cells that were treated with antisense ODN 83 or the scrambled control ODN 82. Briefly, cells were harvested by scraping into PBS and resuspending the subsequent pellet in 100 mM KH<sub>2</sub>PO<sub>4</sub> (pH 7.4). Cells were disrupted by freezing and 25 thawing, followed by sonication. The total protein concentration was determined using Coomassie staining (BioRad reagent) (MI) in order to express results as pmol 5-FdUMP bound per mg total protein. 5-FdUMP binding was assessed in paired lysates from cells transfected with ODN 83 or ODN 32, in separate incubation reactions carried out on different days; however, pairs were always assessed together under the same reaction conditions. On 30 each occasion, the incubation vessel contained 50 µg of total protein, 75 µM methylene-FH<sub>4</sub>, 100 mM mercaptoethanol, 50 mM KH<sub>2</sub>PO<sub>4</sub> (pH 7.4), and 15 nM [6-<sup>3</sup>H]5-FdUMP in a final

-26-

volume of 200 µl. After 30 min at 37°C, the incubation was stopped by addition of 5 volumes of albumin-coated, activated charcoal. After 10 min (room temperature), this slurry was centrifuged (3000 x g, 30 min, 22°C), and the supernatant re-centrifuged to completely remove particulate matter. Two aliquots of 300 µl each were removed from the final, clarified supernatant for scintillation counting.

Statistical analysis:

Data for cell growth after treatment with ODNs alone, or in combination with cytotoxic drugs, are presented as the mean +/- standard error or standard deviation as determined by Student *t*-test. For determinations of FdUMP binding, differences between paired samples from cells transfected with different ODNs were assessed using a paired *t*-test. This controlled for differences in experimental conditions on each of the 5 occasions that FdUMP binding was assessed. In all cases, significance was chosen *a priori* to be indicated by differences at a confidence level of p<0.02.

15

References

Almendral, J.M., *et al.* Mol. Cell. Biol. 8:2140-2148, 1988.  
Ayusawa, D., *et al.* J. Mol. Biol. 190:559-567, 1986.  
Behrend, E.I., *et al.* Cancer Res. 54:832-837, 1994.  
Calvert, A.H., *et al.* J. Clin. Oncol. 4:1245-1252, 1986.  
Chu, E., *et al.* Proc. Natl. Acad. Sci. USA 88:8977-8981, 1991.  
Chu, E., *et al.* Mol. Pharm. 43:527-533, 1993a.  
Chu, E., *et al.* Mol. Cell. Biol. 15:179-185, 1995.  
Chu, E., *et al.* Mol. Cell. Biol. 14:207-213, 1994.  
Chu, E., *et al.* Proc. Natl. Acad. Sci. USA 90:517-521, 1993b.  
Chu, E., *et al.* Cancer Res. 50:5834-5840, 1990.  
Church, G.M., *et al.* Proc. Natl. Acad. Sci. USA 81:1991-1995, 1984.  
Danenberg, P.V., Biochim. Biophys. Acta 473:73-92, 1977.  
DeGregori, J., *et al.* Mol. Cell. Biol. 15:4215-4224, 1995.  
Denhardt, D.T., *et al.* Oncogene 2:55-59, 1988.  
Farnham, P.J., *et al.* Biochim. Biophys. Acta Rev. Cancer 1155:125-131, 1993.

-27-

Hardy, L.W., *et al.* Science 235:448-455, 1987.

Heidelberger, C., *et al.* Adv. Enzymol. 54:58-119, 1983.

Jackman, A.L., *et al.* Adv. Enzyme Regul. 31:13-27, 1991a.

Jackman, A.L., *et al.* Cancer Res. 51:5579-5586, 1991b.

5 Jelinek, W.R., *et al.* Proc. Natl. Acad. Sci. USA 77:1398-1402, 1980.

Jenh, C.-H., *et al.* Mol. Cell. Biol. 5:2527-2532, 1985.

Johnson, L.F. *et al.* J. Cell. Biochem. 54:387-392, 1994.

Karin, M., *et al.* Nucleic Acids Res. 10:3165-3173, 1982.

Keyomarsi, K., *et al.* J. Biol. Chem. 268:15142-15149, 1993.

10 Kikuchi, K., *et al.* J. Biol. Chem. 267:21505-21511, 1992.

Koropatnick, J., *et al.* Proc. Soc. Exp. Biol. Med. 188:287-300, 1988.

Koropatnick, J., *et al.* BioTechniques 22:64-66, 1997.

Koropatnick, J., *et al.* Mol. Biol. Med. 5:69-83, 1988.

Lochshin, A., Proc. Natl. Acad. Sci. USA 76:750-754, 1979.

15 Maley, F., *et al.* J. Biol. Chem. 235:2968-2970, 1960.

Marzluff, W.F., *et al.* IRL Press, Oxford, 89-129, 1984.

M'Kay, R.A., *et al.* Nucleic Acids. Res. 24:411-417, 1996.

Mudrak, I., *et al.* Mol. Cell. Biol. 14:1886-1892, 1994.

Navalgund, L.G., *et al.* J. Biol. Chem. 255:7386-7390, 1980.

20 Peters, G.J., *et al.* Cancer Res. 46:20-28, 1986.

Peters, G.J., *et al.* Eur. J. Cancer 30A:1408-1411, 1994.

Rapaport, E., *et al.* Proc. Natl Acad. Sci. USA 89:8577-8580, 1992.

Sambrook, J., *et al.* T. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1989.

25 Suzuki, M., *et al.* Oncology 51:334-338, 1994.

Takeishi, K., *et al.* Nucleic Acids Res. 13:2035-2043, 1985.

Voeller, D.M., *et al.* Nucleic Acids Res. 23:869-875, 1995.

Volm, M., *et al.* Anticancer Res. 12:2293-2296, 1992.

Volm, M., *et al.* Anticancer Res. 14:1271-1276, 1994.

**CLAIMS**


1. An antisense oligonucleotide which hybridises to a target nucleic acid sequence in thymidylate synthase and which selectively inhibits thymidylate synthase production in 5 mammalian cells.
2. An antisense oligonucleotide which hybridises to a target nucleic acid sequence in thymidylate synthase and which selectively enhances thymidylate synthase production in mammalian cells.
- 10 3. The antisense oligonucleotide of claim 1 or claim 2 comprising SEQ ID No 1, 2, 3, 4, 5, 6, or 7.
4. The antisense oligonucleotide of claim 1 or claim 2 comprising SEQ ID No 8 or 9.
- 15 5. A combination product comprising an antisense oligonucleotide targeted to thymidylate synthase in combination with an anticancer agent.
6. The combination product of claim 5 in which the anticancer agent is a thymidylate 20 synthase inhibitor or a cytostatic agent or an antiproliferative drug.
7. The combination product of claim 5 in which the anticancer agent is Tomudex or ZD9331.
- 25 8. A pharmaceutical composition comprising the combination product of claim 5 and a pharmaceutically acceptable diluent or carrier.
9. A method for the treatment of cancer or for providing an antiproliferative effect which comprises administering to a warm-blooded animal an effective amount of the combination 30 product claimed in claim 4.

-29-


10. Use of the combination product claimed in claim 4 in the production of a new medicament for the treatment of cancer or for treatment of antiproliferative disease.

5

1/13



**Figure 1**



**Figure 2**






Figure 3

4/13




**Figure 4**

5/13




**Figure 5**

6/13

**Figure 6**

7/13

(first 80 bases in TS mRNA not shown)

**Figure 7**

8/13




FIGURE 8

9/13




FIGURE 9

10/13




FIGURE 10

SUBSTITUTE SHEET (RULE 26)

11/13






FIGURE 11

**SUBSTITUTE SHEET (RULE 26)**

12/13

FIGURE 12**SUBSTITUTE SHEET (RULE 26)**

13/13

FIGURE 13

SUBSTITUTE SHEET (RULE 26)

-1-

SEQUENCE LISTING

(1) GENERAL INFORMATION:

5

(i) APPLICANT:

- (A) NAME: Zeneca Ltd
- (B) STREET: 15 Stanhope Gate
- (C) CITY: London
- 10 (D) STATE: Greater London
- (E) COUNTRY: England
- (F) POSTAL CODE (ZIP): W1Y 6LN
- (G) TELEPHONE: 0171 304 5000
- (H) TELEFAX: 0171 304 5151
- 15 (I) TELEX: 0171 834 2042

(ii) TITLE OF INVENTION: COMPOUNDS

(iii) NUMBER OF SEQUENCES: 9

20

(iv) COMPUTER READABLE FORM:

- (A) MEDIUM TYPE: Floppy disk
- (B) COMPUTER: IBM PC compatible
- (C) OPERATING SYSTEM: PC-DOS/MS-DOS
- 25 (D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)

(vi) PRIOR APPLICATION DATA:

- (A) APPLICATION NUMBER: GB 9720107.3
- (B) FILING DATE: 23-SEP-1997

30

(vi) PRIOR APPLICATION DATA:

- (A) APPLICATION NUMBER: GB 9722012.3
- (B) FILING DATE: 17-OCT-1997

35

(vi) PRIOR APPLICATION DATA:

- (A) APPLICATION NUMBER: GB 9812140.3
- (B) FILING DATE: 06-JUN-1998

-2-

(2) INFORMATION FOR SEQ ID NO: 1:

5 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 20 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

10

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

TTAAGGATGT TGCCACTGGC

20

15

(2) INFORMATION FOR SEQ ID NO: 2:

20 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 20 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

25

(ii) MOLECULE TYPE: other nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

30 AATGGCTGTT TAGGGTGCTT

20

(2) INFORMATION FOR SEQ ID NO: 3:

35 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 20 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

40

(ii) MOLECULE TYPE: other nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

45

TGTGGCCGGC TCGGAGCTGC

20

-3-

(2) INFORMATION FOR SEQ ID NO: 4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

GCGCCATGCC TGTGGCCGGC

20

(2) INFORMATION FOR SEQ ID NO: 5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

GCGCCATGCC TGTGGCCGGC

20

(2) INFORMATION FOR SEQ ID NO: 6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

CCCAGCCGCC GCGCCATGCC

20

(2) INFORMATION FOR SEQ ID NO: 7:

-4-

5 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

10 (ii) MOLECULE TYPE: other nucleic acid

15 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

20 ATGCGCCAAC GGTTCCCTAAA

20

25 (2) INFORMATION FOR SEQ ID NO: 8:

20 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 30 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

25 (iii) MOLECULE TYPE: other nucleic acid

30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

30 UGUGGGCCGGC UCGGAGCUGC CGCGCCGGCC

30

35 (2) INFORMATION FOR SEQ ID NO: 9:

35 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 30 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

40 (ii) MOLECULE TYPE: other nucleic acid

45 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

-5-

GGUACAGCCU GAGAGAUGAA UUCCCUCUGC

30

## INTERNATIONAL SEARCH REPORT

Inte. onal Application No

PCT/GB. 98/02820

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/11 C07H21/02 A61K31/70 A61K31/505 //C07D239/95,  
C12N9/10

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C07H A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	JU J.: "INCREASED DRUG SENSITIVITY OF TUMOR CELLS BY MANIPULATION OF CELL CYCLE CONTROL GENES" 1996, THESIS UNIVERSITY OF SOUTHERN CALIFORNIA, PAGE(S) 100 - 130 XP002081365 see the whole document	1,2,5,6, 8-10
Y	---	3,4
A	---	7
Y	EP 0 290 144 A (CITY OF HOPE) 9 November 1988 see page 3, column 1, line 30 - line 39	3
E	WO 98 49287 A (HYBRIDON INC) 5 November 1998 see abstract see page 8; table 1 see claims 1,24	1,2,5,6, 8-10
	---	-/-

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

## \* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

25 February 1999

10/03/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Galli, I

## INTERNATIONAL SEARCH REPORT

Inte onal Application No  
PCT/GB 98/02820

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	<p>FERGUSON P.J. ET AL: "Enhancement of Tomudex cytotoxicity by an antisense oligonucleotide against thymidylate synthase mRNA".          PROCEEDINGS OF THE 89TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, NEW ORLEANS, MARCH 28-APRIL 1, 1998, VOL. 39, PAGE 416, ABSTRACT 2831          XP002094749          see abstract</p> <p>---</p>	1,2,5-10
P,Y	<p>WO 98 33518 A (SLOAN KETTERING INST CANCER ;TONG YOUZHI (US); LIU CHEN XINYUE (US)          6 August 1998          seq ID 37</p> <p>-----</p>	4

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/GB 98/02820

### Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:

Remark: Although claims 9 and 10 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

2.  Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3.  Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.  No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

#### Remark on Protest

The additional search fees were accompanied by the applicant's protest.  
 No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 98/02820

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP 0290144	A 09-11-1988	AU 1556188 A		10-11-1988
		JP 1055199 A		02-03-1989
		US 5736326 A		07-04-1998
		US 5585363 A		17-12-1996
		US 5166140 A		24-11-1992
		US 5814489 A		29-09-1998
WO 9849287	A 05-11-1998	AU 7364998 A		24-11-1998
WO 9833518	A 06-08-1998	NONE		

